Core Laboratories Inc.

Valuation Analysis

About the Company

Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Pr

Core Laboratories Inc. Stock at a Glance

Core Laboratories Inc. (CLB) is currently trading at $13.16 with a market capitalization of $606.6M. The trailing P/E ratio stands at 21.57x, with a forward P/E of 15.39x. The 52-week range spans from $9.72 to $20.36; the current price is 35.4% below the yearly high. Year-over-year revenue growth stands at -1.4%. The net profit margin stands at 5.53%.

💰 Dividend

Core Laboratories Inc. pays an annual dividend of $0.04 per share, representing a yield of 0.3%. The payout ratio stands at 6.56%.

📊 Analyst Rating

3 analysts rate Core Laboratories Inc. (CLB) on consensus: None. The average price target is $16.33, implying +24.11% from the current price. Analyst price targets range from $12.00 to $22.00.

Core Laboratories Inc.: The Investment Case in Detail

Core Laboratories Inc. (CLB) operates in the Energy — specifically Oil & Gas Equipment & Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue is contracting at -1.4% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Short interest sits at 29.5% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

The PEG ratio at 1.44 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 15.39x is meaningfully below the trailing 21.57x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 24.11% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (29.5%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Core Laboratories Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.